|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
To investigate the impact of non-canonical NF-κB signaling on lung carcinogenesis, we employed transgenic mice with doxycycline-inducible expression of p52 in airway epithelial cells. p52 over-expression led to increased tumor number and progression after injection of the carcinogen urethane.
|
29666445 |
2018 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We analysed several ligands and receptors of the alternative NF-κB pathway, RelB, p52 nuclear translocation and target genes in tissue samples of <i>H. pylori</i>-infected patients with different degrees of gastritis or early gastric tumours by in situ hybridisation, immunohistochemistry, Western blot and real-time PCR analyses.
|
27196595 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Consistent with activation of the non-canonical pathway, p52 and RelB co-localized in adenocarcinoma cells in sections of pancreatic tumor tissue, and each of the tumor cell lines displayed elevated p52 levels.
|
19502791 |
2009 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Moreover, nuclear p52 is also associated with LMP1 expression in tumor tissue biopsies.
|
14576816 |
2003 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Together, these studies implicate the non-canonical NF-κB component p52 in lung carcinogenesis and suggest modulation of p52 activity and/or downstream mediators as new therapeutic targets.
|
29666445 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
By selectively overexpressing the p52 subunit in Nfkb2 depleted cells, we found that the increased malignancy in 4T1 cells could not be reverted in the presence of p52, whereas the decreased tumourigenicity of N202.1a cells could be rescued by p52.
|
28190248 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
By selectively overexpressing the p52 subunit in Nfkb2 depleted cells, we found that the increased malignancy in 4T1 cells could not be reverted in the presence of p52, whereas the decreased tumourigenicity of N202.1a cells could be rescued by p52.
|
28190248 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Partial degradation of the p100 subunit to generate p52 subunit is a hallmark of the alternative NF-κB pathway, which has been implicated in cancer.
|
26112410 |
2015 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Partial degradation of the p100 subunit to generate p52 subunit is a hallmark of the alternative NF-κB pathway, which has been implicated in cancer.
|
26112410 |
2015 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In contrast, immunohistochemical and Western blot analyses revealed that p52 Shc was detected in the cytoplasmic fractions obtained from gastric normal mucosa and cancer, while p46 Shc expression was observed in the nuclear fractions from gastric normal mucosa and cancer.
|
15753984 |
2005 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, unlike p52 Shc, p46 Shc was shown to be expressed solely in the nucleus, suggesting that p46 Shc expressed in the nucleus may play an important role in gastric carcinogenesis.
|
15753984 |
2005 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In contrast, immunohistochemical and Western blot analyses revealed that p52 Shc was detected in the cytoplasmic fractions obtained from gastric normal mucosa and cancer, while p46 Shc expression was observed in the nuclear fractions from gastric normal mucosa and cancer.
|
15753984 |
2005 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
A clearer picture is now developing of the important role that p52 NF-kappaB plays during normal cell growth and how subverting its function can contribute to oncogenesis.
|
14576816 |
2003 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
The p52 isoform of SHC1 is a key driver of breast cancer initiation.
|
31202267 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The p52 isoform of SHC1 is a key driver of breast cancer initiation.
|
31202267 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We demonstrate that p52 mediates human BC invasion.
|
30604907 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, the relationship between P36 and P52 during sporozoite invasion remains unknown.
|
30547015 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In patient samples, pTAK1 expression and significant nuclear p65, p50, and p52 localization were detected immunohistochemically in BACH2-negative DLBCL (P < 0.0001, P = 0.006, and P = 0.001, respectively), suggesting that BACH2 downregulation contributes to constitutive activation of the nuclear factor-κB pathway through TAK1 phosphorylation in BACH2-negative DLBCL (most EBV-positive cases).
|
28256087 |
2017 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, NF-κB pathway activation markers P-p65 and p52 predict poor survival in DLBCL patients.
|
25636172 |
2015 |
|
Malaria
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The proteins P52 and P36 are expressed in the sporozoite stage of the murine malaria parasite Plasmodium berghei.
|
23227206 |
2012 |
|
Malaria
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes.
|
18958160 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of p52 impaired bladder cancer invasion by reduction of rhogdiβ mRNA stability and expression.
|
30604907 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of p52 impaired bladder cancer invasion by reduction of rhogdiβ mRNA stability and expression.
|
30604907 |
2019 |